Guilty Plea Adds a Money-Laundering Layer to a $6 Million Medicare Case
A Cape Cod man has pleaded guilty to a money laundering conspiracy tied to a Medicare fraud scheme that generated more than $6 million in health care losses. The plea places financial concealment at the center of the case, not just billing abuse. In health care fraud, the laundering phase often matters as much as the claims phase because it helps move illicit proceeds out of plain sight and gives the underlying scheme room to persist.
Leo Anzivino Jr., 35, of Falmouth, Massachusetts, admitted to conspiring with others to launder health care fraud proceeds. Court documents and statements made in court describe his role as that of a straw or nominee owner of Advanced Medical Supply Corp. In practical terms, nominee ownership can create a false appearance of legitimacy while the real control structure remains hidden. In schemes involving durable medical equipment or other supply businesses, that kind of shell arrangement can make fraudulent payments look like routine reimbursement activity to a payer system built to process claims at scale.
The case is a reminder that Medicare fraud rarely ends with a false claim submission. Once the money lands, the next objective is to preserve access to it, separate it from the original fraud, and disguise its trail through ownership changes, bank accounts, and nominal business fronts. A nominee owner can become the face of the operation without being the true economic actor, which complicates detection and delays recovery.
Straw Ownership and the Mechanics of Concealment
The charging language points to a familiar fraud structure: one or more individuals submit or facilitate claims, then another person steps in to hold title or appear to run the business while the proceeds move through the system. This arrangement can frustrate routine oversight because the outward paperwork no longer reflects the real control pattern. For investigators, ownership records, bank activity, and the flow of Medicare reimbursement become the connective tissue that reveals the operation.
The health care system depends on trust at several points at once. Providers bill, suppliers submit documentation, banks process payments, and regulators rely on records that are often complete only if every participant is honest. When a supplier corporation is used as a straw entity, the fraud reaches beyond one false claim. It distorts the integrity of billing, ownership transparency, and the financial pathways that keep patient-facing services legitimate.
One sentence captures the core problem: false ownership can turn a medical supplier into a laundering vehicle.
That is why financial crime and health care fraud are often investigated together. The proceeds of a scheme are not an afterthought; they are the fuel that keeps the enterprise alive, pays participants, and masks the source of the money. A laundering conspiracy also signals that the scheme had enough scale to require deliberate concealment, which is consistent with the more than $6 million figure attached to the underlying fraud.
Why Medicare Fraud Enforcement Targets the Money Trail
Medicare is vulnerable to fraud precisely because it is large, high-volume, and built to pay legitimate claims quickly. That speed is necessary for patient access, but it also creates opportunities for bad actors to exploit supplier relationships and reimbursement systems. Once fraudulent payments are issued, the government’s job becomes twofold: stop the scheme and follow the funds.
Money laundering statutes are essential in that second step because they allow prosecutors to address conduct that is separate from the original billing fraud. A defendant may not be the person who submitted the false claims, yet still be deeply embedded in the movement of criminal proceeds. In this case, the guilty plea reflects acknowledgment of participation in the laundering conspiracy connected to the broader health care fraud operation.
For compliance programs, the case reinforces how dangerous nominee ownership can be when it is used to obscure control over a medical supply business. Corporate paperwork alone can appear clean while the actual arrangement is designed to bypass scrutiny. Internal controls, ownership verification, and payment monitoring are not administrative extras; they are core safeguards against exactly this kind of misuse.
The Broader Bedside and System-Level Consequences
Health care fraud is often discussed as a financial crime, but its effects reach clinical care. Every dollar diverted through fraudulent billing or laundering is a dollar that does not support appropriate equipment, accurate documentation, or medically necessary services. When a supplier exists mainly to extract Medicare payments, the risk is not abstract. Patients can be exposed to inappropriate equipment, delayed care, or referrals shaped by billing motives rather than clinical need.
The damage is also structural. Fraud schemes degrade trust in the supply chain that clinicians depend on, especially in areas where durable medical equipment, home health services, and other reimbursable supports intersect with vulnerable patients. The more sophisticated the concealment, the harder it becomes for legitimate providers to compete and for payers to separate honest billing from deceptive reimbursement patterns.
A plea in a laundering case does not resolve every question in the larger fraud investigation, but it does confirm one critical point: the proceeds were not left exposed. They were handled in a way intended to obscure their origin, and the nominee-owner structure was part of that design. In enforcement terms, that can help prosecutors map the enterprise, connect participants, and establish how the money moved after the fraud was committed.
A Case Built on Financial Concealment, Not Clinical Claims
The action arose from the U.S. Department of Justice and the U.S. Attorney’s Office for the District of New Hampshire, with HHS-OIG listing both criminal and civil actions. The action details list Oct. 13, 2026, at 8:37 p.m., though the substantive narrative centers on a guilty plea entered today in connection with the same fraud scheme. The core clinical relevance lies in the system abuse itself: a Medicare reimbursement channel was exploited, and the proceeds were then laundered through a nominee-owned company.
What remains unresolved from the public summary is the full scope of the underlying billing conduct and the identities of all co-conspirators. The available details also do not describe whether any patients were directly harmed by specific claims or whether additional charges are pending. Those facts may emerge elsewhere, but the public record here is centered on the laundering conspiracy and the use of Advanced Medical Supply Corp. as the ownership vehicle.
For health care organizations, the case is a sharp reminder that reimbursement fraud is rarely just a claims problem. It is a governance problem, a documentation problem, and a money-trail problem all at once. When those layers collapse into one scheme, detection requires more than chart review; it requires financial scrutiny, ownership transparency, and aggressive follow-through once suspicious payments begin to accumulate.